Le Lézard
Classified in: Health
Subjects: PDT, IMA

Rapid Medical Receives CE Mark for TIGERTRIEVERtm XL


TIGERTRIEVER XL is the largest stentriever available, designed to safely remove clots from intracranial vessels up to 9mm in diameter

YOKNEAM, Israel, July 27, 2020 /PRNewswire/ -- Rapid Medical, a company focused on the development of next generation neurovascular devices, has announced that it received CE Mark for TIGERTRIEVER XL. In addition, the first patients have been treated successfully with the device.

 

Clot removed from the brain of the 1st stroke patient treated with Tigertriever XL at Bochum University Hospital

 

The TIGERTRIEVER family of stentrievers are the first-ever adjustable, fully visible clot retrievers designed to treat ischemic stroke. Thousands of patients have been successfully treated with TIGERTRIEVER to date. TIGERTRIEVER XL is the newest addition to the portfolio. Its adjustable diameter can conform to any vessel diameter up to 9mm and at 53mm in length, it is the largest and the longest stentriever available. Although significantly larger than other similar devices on the market, it is easily delivered via a standard microcatheter with an internal diameter of 0.021".

"TIGERTRIEVER XL is a very important addition to the ischemic stroke market," said Dr. Sebastian Fischer, a senior Interventional Neuroradiologist at Bochum University Hospital, Germany. "For the first time, we have a tool that can be adjusted to these dimensions and is dedicated to retrieve large clot loads. This is an important addition to our current tool set, since it can potentially reduce the number of passes required to remove large stroke-causing clots, for example, in the internal carotid artery."

Ronen Eckhouse, CEO of Rapid Medical commented on the first clinical experience with TIGERTRIEVER XL: "TIGERTRIEVER XL is another example of our powerful technology that adjusts to the vessel diameter for full clot removal in the treatment large vessel occlusion. TIGERTRIEVER XL compliments TIGERTRIEVER 13, the smallest stentriever available today, and the only stentriever indicated for distal vessel occlusion. The TIGERTRIEVER portfolio now allows surgeons to treat ischemic stroke in the majority of vessels where it occurs."

About Rapid Medical

Rapid Medical is developing game-changing devices for neurovascular treatments. Rapid Medical is the maker of TIGERTRIEVERtm and COMANECItm, the first-ever adjustable remodeling mesh. TIGERTRIEVER and COMANECI are CE marked for use in Europe and COMANECI is also FDA approved. More information is available at www.rapid-medical.com

Contact:
Ronen Eckhouse
+972-72-2503331
[email protected]


These press releases may also interest you

at 09:08
MyFitnessPal, the #1 global nutrition and food tracking app, today announced that it has appointed Tim Holley as Chief Product Officer. In this role, Tim will apply his extensive experience driving sustained growth through reliable delivery of...

at 09:05
MDI Health, an AI-powered solution that optimizes personalized medication management at scale, announced that it has been selected as winner of the "Best New Technology Solution for Medication Management" award in the 8th annual MedTech Breakthrough...

at 09:02
Lumenis Be Ltd., a leading energy-based medical device company for aesthetic and eye care applications, announced today that triLift is the winner of the highly competitive "Best New Dermatology Technology Solution" award in the 8th annual MedTech...

at 09:00
Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024...

at 09:00
Medtech Canada, the national association representing Canada's medical technology companies, is very pleased to welcome James Brodie of Johnson & Johnson MedTech as Chair of the Medtech Canada Board of Directors. He is joined by five new board...

at 09:00
Amidst a landscape of resilience and renewal, the Leukemia & Lymphoma Society of Canada proudly announces the triumphant return of Light The Night, scheduled to illuminate at Parc Jean-Drapeau, Espace Paddock on October 26, 2024. As peer-to-peer...



News published on and distributed by: